title: EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy.
abstract: Screening for EGFR mutation is a key molecular test for management of lung cancer patients. Outcome of patients with mutation receiving EGFR tyrosine kinase inhibitor is known to be better across different ethnic populations. However, frequency of EGFR mutations and the clinical response in most other ethnic populations, including India, remains to be explored. We conducted a retrospective analysis of Indian lung cancer patients who were managed with oral tyrosine kinase inhibitors. Majority of the patients in the study had adenocarcinoma and were non-smokers. 39/111 patients tested positive for EGFR kinase domain mutations determined by Taqman based real time PCR. The overall response to oral TKI therapy was 30%. Patients with an activating mutation of EGFR had a response rate of 74%, while the response rate in patients with wild type EGFR was 5%, which was a statistically significant difference. Progression free survival of patients with EGFR mutations was 10 months compared to 2 months for EGFR mutation negative patients. Overall survival was 19 months for EGFR mutation patients and 13 months for mutation negative patients. This study emphasizes EGFR mutation as an important predictive marker for response to oral tyrosine kinase inhibitors in the Indian population.
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India.
authors.forename: Vanita
authors.initials: V
authors.lastname: Noronha
authors.forename: Kumar
authors.initials: K
authors.lastname: Prabhash
authors.forename: Abhishek
authors.initials: A
authors.lastname: Thavamani
authors.forename: Anuradha
authors.initials: A
authors.lastname: Chougule
authors.forename: Nilendu
authors.initials: N
authors.lastname: Purandare
authors.forename: Amit
authors.initials: A
authors.lastname: Joshi
authors.forename: Rashmi
authors.initials: R
authors.lastname: Sharma
authors.forename: Saral
authors.initials: S
authors.lastname: Desai
authors.forename: Nirmala
authors.initials: N
authors.lastname: Jambekar
authors.forename: Amit
authors.initials: A
authors.lastname: Dutt
authors.forename: Rita
authors.initials: R
authors.lastname: Mulherkar
mesh_terms: D000284:Administration, Oral; D003710:Demography; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D005260:Female; D005820:Genetic Testing; D006801:Humans; D007194:India; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009154:Mutation / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D060888:Real-Time Polymerase Chain Reaction; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors